GB201400034D0 - Pharmaceutical Compositions comprising AZD9291 - Google Patents
Pharmaceutical Compositions comprising AZD9291Info
- Publication number
- GB201400034D0 GB201400034D0 GBGB1400034.3A GB201400034A GB201400034D0 GB 201400034 D0 GB201400034 D0 GB 201400034D0 GB 201400034 A GB201400034 A GB 201400034A GB 201400034 D0 GB201400034 D0 GB 201400034D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- azd9291
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 title 1
- 229960003278 osimertinib Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (44)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
| UY0001035933A UY35933A (es) | 2014-01-02 | 2014-12-29 | Composiciones farmacéuticas que comprenden azd9291 |
| ARP140104947A AR098989A1 (es) | 2014-01-02 | 2014-12-29 | Composiciones farmacéuticas que comprenden azd9291 |
| TW103146652A TWI702953B (zh) | 2014-01-02 | 2014-12-31 | 包含ａｚｄ９２９１之醫藥組合物及錠劑以及其用途 |
| SG11201605339QA SG11201605339QA (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| PH1/2016/501310A PH12016501310B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| MYPI2016702433A MY183536A (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| CN201580003266.4A CN105848647B (zh) | 2014-01-02 | 2015-01-02 | 包含azd9291的药用组合物 |
| SI201531610T SI3089741T1 (sl) | 2014-01-02 | 2015-01-02 | Farmacevtski sestavek, ki vsebuje AZD9291 |
| HUE15700082A HUE054344T2 (hu) | 2014-01-02 | 2015-01-02 | Gyógyászati készítmények AZD9291 tartalommal |
| MX2016008744A MX367358B (es) | 2014-01-02 | 2015-01-02 | Composiciones farmaceuticas que comprenden azd9291. |
| SM20210330T SMT202100330T1 (it) | 2014-01-02 | 2015-01-02 | Composizioni farmaceutiche comprendenti azd9291 |
| HK16114195.6A HK1225655B (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| KR1020167020731A KR102336378B1 (ko) | 2014-01-02 | 2015-01-02 | Azd9291을 포함하는 제약 조성물 |
| PL15700082T PL3089741T3 (pl) | 2014-01-02 | 2015-01-02 | Kompozycje farmaceutyczne zawierające AZD9291 |
| CN202210324141.3A CN114712362A (zh) | 2014-01-02 | 2015-01-02 | 包含azd9291的药用组合物 |
| ES15700082T ES2873226T3 (es) | 2014-01-02 | 2015-01-02 | Composiciones farmacéuticas que comprenden AZD9291 |
| US15/109,170 US10183020B2 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising AZD9291 |
| PE2016000943A PE20161170A1 (es) | 2014-01-02 | 2015-01-02 | Composiciones farmaceuticas que comprenden azd9291 |
| RS20210698A RS61927B1 (sr) | 2014-01-02 | 2015-01-02 | Farmaceutske supstance koje sadrže azd9291 |
| CR20160310A CR20160310A (es) | 2014-01-02 | 2015-01-02 | Composiciones farmacpeuticas que comprenden azd9291 |
| PT157000829T PT3089741T (pt) | 2014-01-02 | 2015-01-02 | Composições farmacêuticas compreendendo azd9291 |
| AU2015204218A AU2015204218B2 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising AZD9291 |
| CA2933403A CA2933403C (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| PCT/GB2015/050001 WO2015101791A1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| EP15700082.9A EP3089741B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| JP2016544368A JP6588915B2 (ja) | 2014-01-02 | 2015-01-02 | Ａｚｄ９２９１を含む医薬組成物 |
| HRP20210749TT HRP20210749T1 (hr) | 2014-01-02 | 2015-01-02 | Farmaceutski pripravci koji sadrže azd9291 |
| LTEP15700082.9T LT3089741T (lt) | 2014-01-02 | 2015-01-02 | Farmacinės kompozicijos apimančios azd9291 |
| EA201691242A EA034243B9 (ru) | 2014-01-02 | 2015-01-02 | Фармацевтические композиции, содержащие azd9291, для лечения рака |
| NZ721298A NZ721298A (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| DK15700082.9T DK3089741T3 (da) | 2014-01-02 | 2015-01-02 | Farmaceutiske sammensætninger omfattende azd9291 |
| IL246186A IL246186B (en) | 2014-01-02 | 2016-06-13 | Pharmaceutical preparations containing azd9291 |
| CL2016001609A CL2016001609A1 (es) | 2014-01-02 | 2016-06-22 | Composiciones farmacéuticas que comprenden azd9291. |
| DO2016000156A DOP2016000156A (es) | 2014-01-02 | 2016-06-22 | Composiciones farmacã¿uticas que comprenden azd9291. |
| GT201600142A GT201600142A (es) | 2014-01-02 | 2016-06-29 | Composiciones farmacéuticas que comprenden azd9291 |
| NI201600098A NI201600098A (es) | 2014-01-02 | 2016-07-01 | Composiciones farmacéuticas que comprenden azd9291 |
| ZA2016/05300A ZA201605300B (en) | 2014-01-02 | 2016-08-01 | Pharmaceutical compositions comprising azd9291 |
| US16/196,185 US20190111057A1 (en) | 2014-01-02 | 2018-11-20 | Pharmaceutical compositions comprising azd9291 |
| US16/984,276 US20200360378A1 (en) | 2014-01-02 | 2020-08-04 | Pharmaceutical compositions comprising azd9291 |
| CY20211100499T CY1124848T1 (el) | 2014-01-02 | 2021-06-08 | Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291 |
| US17/478,117 US20240189310A1 (en) | 2014-01-02 | 2021-09-17 | Pharmaceutical compositions comprising azd9291 |
| US17/729,162 US20220395502A1 (en) | 2014-01-02 | 2022-04-26 | Pharmaceutical compositions comprising azd9291 |
| US18/897,609 US20250017930A1 (en) | 2014-01-02 | 2024-09-26 | Pharmaceutical compositions comprising azd9291 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201400034D0 true GB201400034D0 (en) | 2014-02-19 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1400034.3A Ceased GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| KR20260009945A (ko) | 2018-02-12 | 2026-01-20 | 아스트라제네카 아베 | 비-소세포 폐암의 치료에 사용하기 위한 오시메르티닙 |
| KR20250002710A (ko) * | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| CN109496150A (zh) * | 2018-03-23 | 2019-03-19 | 无锡双良生物科技有限公司 | 一种药物组合物及其制备方法和用途 |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR20210144844A (ko) | 2019-03-29 | 2021-11-30 | 아스트라제네카 아베 | 비-소세포 폐암의 치료에 사용하기 위한 오시머티닙 |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| JP2023510426A (ja) | 2020-01-20 | 2023-03-13 | アストラゼネカ・アクチエボラーグ | 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (zh) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| PE20250268A1 (es) | 2022-04-28 | 2025-01-29 | Astrazeneca Ab | Compuestos heteroaromaticos biciclicos condensados y uso en el tratamiento del cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| EP4543920A1 (en) | 2022-06-27 | 2025-04-30 | Astrazeneca AB | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN119654152A (zh) | 2022-07-08 | 2025-03-18 | 阿斯利康(瑞典)有限公司 | 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| TWI901422B (zh) * | 2023-10-31 | 2025-10-11 | 大陸商浙江同源康醫藥股份有限公司 | 一種嘧啶類衍生物的藥物組合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| KR20100090726A (ko) | 2002-02-26 | 2010-08-16 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
| CA2582299A1 (en) * | 2004-10-05 | 2006-04-13 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| JP5133071B2 (ja) * | 2006-02-09 | 2013-01-30 | 第一三共株式会社 | 抗癌医薬組成物 |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| EP2170062A4 (en) * | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
| WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| CN103702990B (zh) * | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| EP2802314B1 (en) * | 2012-01-13 | 2020-11-25 | XSpray Microparticles AB | A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component. |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active Active
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/it unknown
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201605300B (en) | Pharmaceutical compositions comprising azd9291 | |
| GB201419257D0 (en) | Pharmaceutical compositions | |
| GB201618482D0 (en) | Pharmaceutical compositions | |
| GB201409471D0 (en) | Pharmaceutical composition | |
| IL249553A0 (en) | Pharmaceutical preparations | |
| GB201409488D0 (en) | Pharmaceutical composition | |
| GB201409485D0 (en) | Pharmaceutical composition | |
| ZA201702086B (en) | Long acting pharmaceutical compositions | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| PT3200772T (pt) | Composições farmacêuticas compreendendo alpelisib | |
| PL3122330T3 (pl) | Kompozycje farmaceutyczne zawierające lewocetyryzynę | |
| ZA201508726B (en) | Pharmaceutical composition | |
| ZA201502073B (en) | Pharmaceutical composition | |
| IL255510A (en) | Pharmaceutical compositions | |
| IL250817A0 (en) | pharmaceutical preparations | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| PL3089740T3 (pl) | Kompozycja farmaceutyczna | |
| SG10201504332VA (en) | Pharmaceutical Composition | |
| HUE055943T2 (hu) | Anagrelidet tartalmazó gyógyszerkészítmények | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| GB201520762D0 (en) | Novel pharmaceutical compositions | |
| SG2014014872A (en) | Pharmaceutical compositions | |
| GB201408432D0 (en) | Pharmaceutical compositions | |
| PL3319596T3 (pl) | Farmaceutyczne kompozycje |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |